Literature DB >> 1746068

Case control study of cerebral perfusion deficits in divers using 99Tcm hexamethylpropylene amine oxime.

M Hodgson1, D J Smith, M A Macleod, A S Houston, T J Francis.   

Abstract

In a preliminary report, Adkisson et al. (Lancet 1989; 2:119-121) used 99Tcm-hexamethylpropylene amine oxime (HMPAO) single photon emission computed tomography (SPECT) to provide evidence for cerebral perfusion deficits in 28 cases of dysbarism. The report caused concern because these deficits were found even in cases in which the clinical manifestations were limited to the spinal cord. To address this issue further, a case-control study of cerebral perfusion using 99Tcm-HMPAO SPECT is reported. Four groups of 10 subjects were studied: a) divers scanned on average 11 days after treatment of neurologic decompression illness, b) divers scanned 3-5 yr after treatment for neurologic decompression illness, c) diver controls, and d) population controls. All groups were matched for age, and the divers were further matched for general diving experience. The scans were randomized and reported blind to history. Despite a trend toward larger numbers of deficits in individuals with decompression illness, the 4 groups were statistically indistinguishable. Furthermore, no correlation was found between the location of the perfusion deficits and the clinical presentation. These results indicate that 99Tcm-HMPAO SPECT scanning requires further evaluation before clinical significance can be ascribed to perfusion deficits found in divers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1746068

Source DB:  PubMed          Journal:  Undersea Biomed Res        ISSN: 0093-5387


  1 in total

1.  Correlation between 99Tcm-HMPAO-SPECT brain image and a history of decompression illness or extent of diving experience in commercial divers.

Authors:  T G Shields; P M Duff; S A Evans; H G Gemmell; P F Sharp; F W Smith; R T Staff; S E Wilcock
Journal:  Occup Environ Med       Date:  1997-04       Impact factor: 4.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.